Distinct requirements for Ras oncogenesis in human versus mouse cells

Genes and Development

Volumn 16, Issue 16, 2002, Pages 2045-2057

  Hamad, Nesrin M ^a   Elconin, Joel H ^a,d   Karnoub, Antoine E ^c   Bai, Wenli ^a   Rich, Jeremy N ^b   Abraham, Robert T ^a,e   Der, Channing J ^c   Counter, Christopher M ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d New Mexico Oncology Hematology Consultants   (United States)

^e BURNHAM INSTITUTE   (United States)

Author keywords

Human; RalGEF; Ras; Transformation; Tumorigenesis

Indexed keywords

CELL PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAF PROTEIN; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; ENZYME ACTIVATION; FIBROBLASTS; HUMANS; IMMUNOBLOTTING; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASMS; RAL GUANINE NUCLEOTIDE EXCHANGE FACTOR; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE;

EID: 0037102561     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.993902     Document Type: Article

References (87)

1. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1
2. N-terminal domains of the human telomerase catalytic subunit required for enzyme activity in vivo
3. DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood
4. Extension of life-span by introduction of telomerase into normal human cells
5. Structure and biological activity of human homologs of the raf/mil oncogene
6. ras oncogenes in human cancer: A review
7. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
8. Simian virus 40-like DNA sequences in human pleural mesothelioma
9. Genetic origin of mutations predisposing to retinoblastoma
10. Telomerase activity in normal and malignant murine tissues
11. Correlation of pattems of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma
12. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene
13. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization
14. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells
15. Ras effectors: Buying shares in Ras plc
16. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
17. rsc: A novel oncogene with structural and functional homology with the gene family of exchange factors for Ral
18. RalGEF2, a pleckstrin homology domain containing guanine nucleotide exchange factor for Ral
19. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors
20. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
21. Structure determination of the Rasbinding domain of the Ral-specific guanine nucleotide exchange factor Rlf
22. Guanine nucleotide binding properties of the mammalian RalA protein produced in Escherichia coli
23. Ralspecific guanine nucleotide exchange factor activity opposes other Ras effectors in PC12 cells by inhibiting neurite outgrowth
24. Inhibition of telomerase is related to the lifespan and tumorigenicity of human prostate cancer cells
25. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation
26. Creation of human tumor cells with defined genetic elements
27. Enumeration of the simian virus 40 early region elements necessary for human cell transformation
28. Protein binding and signaling properties of RIN1 suggest a unique effector function
29. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
30. Effects of an Rb mutation in the mouse
31. Tumor predisposition in mice heterozygous for a targeted mutation in Nf1
32. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
33. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation
34. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation
35. Tumors associated with p53 germline mutations: A synopsis of 91 families
36. RAS inhibitors: Potential for cancer therapeutics
37. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells
38. Raf-1 activates MAP kinase-kinase
39. Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors
40. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
41. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumor suppressor gene hypothesis
42. Thermodynamic and kinetic characterization of the interaction between the Ras binding domain of AF6 and members of the Ras subfamily
43. Functional analysis of the retinoblastoma gene product and of RB-SV40 T antigen complexes
44. Phospholipase D and RalA cooperate with the epidermal growth factor receptor to transform 3Y1 rat fibroblasts
45. Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53
46. PIK3CA as an oncogene in cervical cancer
47. Transformation of mammalian cells by constitutively active MAP kinase kinase
48. SV40 early region and large T antigen in human brain tumors, peripheral blood cells, and sperm fluids from healthy individuals
49. Transforming c-Ki-ras mutation is a preneoplastic event in mouse mammary carcinogenesis induced in vitro by N-methyl-N-nitrosourea
50. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
51. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line
52. Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation
53. Reversing time: Origin of telomerase
54. Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells
55. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A
56. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors
57. An essential role for Rac in Ras transformation
58. A role for RalGDS and a novel Ras effector in the Ras-mediated inhibition of skeletal myogenesis
59. Identification and characterization of a new family of guanine nucleotide exchange factors for the ras-related GTPase Ral
60. A genetically tractable model of human glioma formation
61. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation
62. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras
63. Role of small t antigen in the acute transforming activity of SV40
64. A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras
65. Development of anticancer drugs targeting the MAP kinase pathway
66. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
67. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
68. A novel RalGEF-like protein, RGL3, as a candidate effector for rit and Ras
69. A survey of telomerase activity in human cancer
70. Understanding Ras: 'It ain't over 'til it's over'
71. Mutants of SV40 with an altered small t protein are reduced in their ability to transform cells
72. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter
73. Dissociation of anchorage independence from tumorigenicity in human cell hybrids
74. Definition of the human raf amino-terminal regulatory region by deletion mutagenesis
75. PI3-kinase inhibition: A target for drug development?
76. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
77. Activation of Raf as a result of recruitment to the plasma membrane
78. Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene
79. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation
80. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span
81. Signal pathways which promote invasion and metastasis: Critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways
82. Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signalregulated kinases
83. Multiple Ras functions can contribute to mammalian cell transformation
84. A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation
85. Ras caught in another affair: The exchange factors for Ral
86. Stimulation of gene induction and cell growth by the Ras effector Rlf
87. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats